(Alliance News) - 4D Pharma PLC on Friday said its has joined the Parkinson's Progression Markers Initiative, a study for the better understanding of Parkinson's disease and the development of new treatments, sponsored by the Michael J Fox Foundation.
The study was first launched in 2010 to help identify, develop, and validate biomarkers of Parkinson's disease progression to further the development of disease-modifying therapies.
Under the initiative, the Leeds-based pharmaceutical company will contribute towards the programme by joining the Partner Scientific Advisory Board, which is involved in the design of the study. In addition, 4D Pharma will also join several working groups for the discussion of data and address Parkinson's clinical trial challenges with other partners.
"The Michael J Fox Foundation has made considerable contributions to the development of therapeutic solutions for the millions of people with Parkinson's disease. Joining the PPMI Scientific Advisory Board will enable 4D Pharma to bring its leading expertise in Liv eBiotherapeutics and the gut-brain axis to the pioneering joint effort that is the PPMI," said Chief Scientific Officer Alex Stevenson.
Shares in 4D Pharma were up 4.3% at 101.60 pence on Friday in London.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
